Type 1 diabetes: Prescription of GLP-1 receptor agonists and SGLT2 inhibitors

被引：0
|
作者：
Simon, Annika
机构：
来源：
DIABETOLOGIE UND STOFFWECHSEL | 2025年 / 20卷 / 01期
关键词：
D O I：
10.1055/a-2451-3561
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Two relatively new classes of antidiabetic drugs - GLP-1 receptor agonists (GLP-1-RAs) and SGLT2 inhibitors (SGLT2-Is) - show positive effects on cardiovascular mortality and weight management in people with type 2 diabetes. Since there is also evidence that patients with type 1 diabetes could also benefit, Li et al. conducted a data analysis on current prescribing practices.
引用
收藏
页码：23 / 23
页数：1
相关论文
共 50 条
  • [31] Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
    Brown, Emily
    Wilding, John P. H.
    Barber, Thomas M.
    Alam, Uazman
    Cuthbertson, Daniel J.
    OBESITY REVIEWS, 2019, 20 (06) : 816 - 828
  • [32] Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
    Wright, Alison K. K.
    Carr, Matthew J. J.
    Kontopantelis, Evangelos
    Leelarathna, Lalantha
    Thabit, Hood
    Emsley, Richard
    Buchan, Iain
    Mamas, Mamas A. A.
    van Staa, Tjeerd P. P.
    Sattar, Naveed
    Ashcroft, Darren M. M.
    Rutter, Martin K. K.
    DIABETES CARE, 2022, 45 (04) : 909 - 918
  • [33] Treatment discontinuation among users of SGLT2 inhibitors and GLP-1 receptor agonists in a national population of patients with type 2 diabetes
    Lim, C. -E.
    Pasternak, B.
    Eliasson, B.
    Ueda, P.
    DIABETOLOGIA, 2024, 67 : S205 - S205
  • [34] The Combined Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Cardiovascular Events among Patients with Type 2 Diabetes
    Azoulay, Laurent
    Simms-Williams, Nikita
    Yin, Hui
    Lu, Sally
    Treves, Nir
    Yu, Oriana Hoi Yun
    DIABETES, 2023, 72
  • [35] GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis
    Banerjee, Mainak
    Pal, Rimesh
    Maisnam, Indira
    Mukhopadhyay, Satinath
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2024, 18 (01)
  • [36] GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis
    Karagiannis, Thomas
    Tsapas, Apostolos
    Athanasiadou, Eleni
    Avgerinos, Ioannis
    Liakos, Aris
    Matthews, David R.
    Bekiari, Eleni
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 174
  • [37] SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
    Gurgle, Holly E.
    White, Karen
    McAdam-Marx, Carrie
    VASCULAR HEALTH AND RISK MANAGEMENT, 2016, 12 : 239 - 249
  • [38] Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
    Tang, Mengyao
    Morieri, Mario Luca
    Kalim, Sahir
    Doria, Alessandro
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2025,
  • [39] GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?
    Santulli, Gaetano
    Mone, Pasquale
    Varzideh, Fahimeh
    FUTURE CARDIOLOGY, 2025, 21 (01) : 5 - 8
  • [40] SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: BMJ Rapid Recommendation
    Arnold, Michael J.
    Buelt, Andrew
    AMERICAN FAMILY PHYSICIAN, 2022, 105 (06) : 675 - 677
12345